钙调磷酸酶抑制剂致肾损伤的研究进展

doi:10.20047/j.issn1673-7210.2023.21.11

Abstract
Figure/Table
References (39)
Related Citation (15)

Download: PDF (588 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Calcineurin inhibitor (CNI) is a kind of widely used immunosuppressive drug. Ciclosporin A and Tacrolimus are commonly used in clinic. CNI exerts immunosuppressive effects by inhibiting T cell activation, inducing T cell apoptosis, and inhibiting the expression of various immune factors, and has significant therapeutic effects on autoimmune diseases such as systemic lupus erythematosus and membranous nephropathy. Meanwhile, CNI also has toxic side effects that can cause kidney damage. CNI can damage the glomerulus, renal microvasculature, renal tubules, and renal interstitium to varying degrees by activating the renin-angiotension-aldosterone system, destroying the balance of local vasoactive substances in the kidney, promoting oxidative stress, and other ways. Urinary retinol binding protein and other biomarkers may have some value in early detection of renal injury caused by CNI. Calcium channel blocker is considered as an effective means to alleviate CNI induced renal injury. This article aims to provide theoretical basis and prevention and treatment ideas for renal injury caused by CNI, and promote the rational and safe use of CNI in clinical practice.

Key words： Calcineurin inhibitor Renal injury Calcium channel blocker Tacrolimus

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Xuan1　ZHANG Kunying2

Cite this article:

SUN Xuan1　ZHANG Kunying2. Research progress on renal injury induced by calcineurin inhibitor[J]. 中国医药导报, 2023, 20(24): 48-51.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.21.11 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I24/48

[1] Parlakpinar H，Gunata M. Transplantation and immunosuppression：a review of novel transplant-related immunosuppressant drugs [J]. Immunopharmacol Immunotoxicol，2021， 43（6）：651-665.
[2] Ume AC，Wenegieme TY，Williams CR. Calcineurin inhibitors：a double-edged sword [J]. Am J Physiol Renal Physiol，2021， 320（3）：F336-F341.
[3] Bentata Y. Tacrolimus：20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity [J]. Artif Organs，2020，44（2）：140-152.
[4] 郭慧蕾，徐进，张永，等.钙调蛋白抑制剂致肾损伤45例文献分析[J].中南药学，2015，13（10）：1100-1104.
[5] Farouk SS，Rein JL. The many faces of calcineurin inhibitor toxicity—What the FK? [J]. Adv Chronic Kidney Dis，2020， 27（1）：56-66.
[6] 吴鹏飞，刘俊麟，崔志峰.钙调磷酸酶-活化T细胞核因子信号通路抑制剂的研究进展[J].中国药理学与毒理学杂志，2016，30（4）：397-404.
[7] Rusnak F，Mertz P. Calcineurin：form and function [J]. Physiol Rev，2000，80（4）：1483-1521.
[8] 刘蕴星，束庆，姚瑶，等.环孢素代谢相关酶基因多态性对其药动学及药效学的影响[J].中国医院药学杂志，2019，39（10）：1007-1012.
[9] 周建平.环孢素A致肾脏慢性损伤机理的探讨[D].北京：中国人民解放军军事医学科学院，2004.
[10] 方茜，屈强，肖湘成.他克莫司治疗特发性膜性肾病研究进展[J].中国临床药理学与治疗学，2019，24（2）：228- 234.
[11] 黄珀，邓勇，张春梅，等.大鼠环孢霉素A中毒性肾损伤模型的探讨[J].泸州医学院学报，2013，36（4）：347-349.
[12] 潘铁军，唐礼功，文瀚东，等.环孢素A移植肾毒性损害的病理变化[J].中华泌尿外科杂志，2003，24（3）：178- 179.
[13] 陈嘉薇.环孢素A肾毒性机制的研究进展[J].中华器官移植杂志，2003，24（4）：255-256.
[14] English J，Evan A，Houghton DC，et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function [J]. Transplantation，1987，44（1）：135-141.
[15] Shrestha BM. Two decades of tacrolimus in renal transplant：basic science and clinical evidences [J]. Exp Clin Transplant，2017，15（1）：1-9.
[16] 赵学智，黎磊石.环孢素A肾毒性的血流动力学机制[J].国外医学泌尿系统分册，1992，12（4）：155-159.
[17] Fu R，Tajima S，Suetsugu K，et al. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation [J]. Acta Pharmacol Sin，2019，40（2）：151-159.
[18] 刘其锋，郁丽霞，李莎莎，等.Rg1对环孢素A慢性肾毒性大鼠肾脏肾小管上皮-间充质细胞转分化的抑制作用[J].中国药物与临床，2014，14（6）：736-738.
[19] 全文淑，金英顺，金吉哲，等.过度内质网应激在慢性环孢素A肾毒性细胞凋亡中的作用机制[J].中国病理生理杂志，2014，30（6）：1047-1051.
[20] 桑义民，王淑秋.环孢素A移植肾毒性损害的病理特点及其临床应用探讨[J].中国医学创新，2019，16（20）：71-74.
[21] Hammoud SH，Alkhansa S，Mahjoub N，et al. Molecular basis of the counteraction by calcium channel blockers of cyclosporine nephrotoxicity [J]. Am J Physiol Renal Physiol，2018，315（3）：F572-F582.
[22] Moon D，Kim J. Cyclosporin A aggravates hydrogen peroxide-induced cell death in kidney proximal tubule epithelial cells [J]. Anat Cell Biol，2019，52（3）：312-323.
[23] Camara NO，Matos AC，Rodrigues DA，et al. Urinary retinol binding protein is a good marker of progressive cyclosporine nephrotoxicity after heart transplant [J]. Transplant Proc，2001，33（3）：2129-2131.
[24] Carlos CP，Sonehara NM，Oliani SM，et al. Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model [J]. PLoS One，2014，9（7）：e103660.
[25] Gonzalez-Guerrero C，Cannata-Ortiz P，Guerri C，et al. TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity [J]. Arch Toxicol，2017，91（4）：1925-1939.
[26] Cheng CH，Shu KH，Chang HR，et al. Cyclosporine-induced tubular vacuolization：the role of Bip/Grp78 [J]. Nephron Exp Nephrol，2012，122（1-2）：1-12.
[27] Dworkin LD，Benstein JA，Parker M，et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms [J]. Kidney Int，1993，43（4）：808- 814.
[28] Shalaby U. Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation [J]. Jpn J Ophthalmol，2017，61（2）：169-178.
[29] Duvoux C，Cherqui D，Di Martino V，et al. Nicardipine as antihypertensive therapy in liver transplant recipients：results of long-term use [J]. Hepatology，1997，25（2）：430- 433.
[30] Luo K，Lim SW，Jin J，et al. Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties [J]. BMC Nephrol，2019，20（1）：221.
[31] Yilmaz N，Ilhan S，Naziroglu M，et al. Ceftriaxone ameliorates cyclosporine A-induced oxidative nephrotoxicity in rat [J]. Cell Biochem Funct，2011，29（2）：102-107.
[32] El-Kashef DH，El-Kenawi AE，Suddek GM，et al. Allicin ameliorates kidney function and urinary bladder sensitivity in cyclosporine A-treated rats [J]. Hum Exp Toxicol，2017， 36（7）：681-691.
[33] Lin CX，Li Y，Liang S，et al. Metformin attenuates cyclosporine A-induced renal fibrosis in rats [J]. Transplantation，2019，103（10）：e285-e296.
[34] Li J，Li H，Li Q，et al. Repaglinide inhibits cyclosporine A-induced renal tubular toxicity by affecting apoptosis and Bax and Bcl-2 expression [J]. Turk J Med Sci，2018，48（4）：880-885.
[35] Fernando ME，Sellappan M，Srinivasa PN，et al. Influence of CYP3A5 and ABCB1 polymorphism on tacrolimus drug dosing in South Indian renal allograft recipients [J]. Indian J Nephrol，2019，29（4）：261-266.
[36] Maestri M，Dafoe DC，Adams GA，et al. Insulin-like growth factor-Ⅰ ameliorates delayed kidney graft function and the acute nephrotoxic effects of cyclosporine [J]. Transplantation，1997，64（2）：185-190.
[37] El-Gowilly SM. Metoprolol ameliorates cyclosporine a-induced hypertension and nephrotoxicity in rats [J]. J Cardiovasc Pharmacol，2011，58（6）：639-646.
[38] Wang C，Salahudeen AK. Lipid peroxidation accompanies cyclosporine nephrotoxicity：effects of vitamin E [J]. Kidney Int，1995，47（3）：927-934.
[39] Hosogai N，Tomita M，Hamada K，et al. Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats [J]. Eur J Pharmacol，2003，477（2）：171-178.